CA2225627A1 - Azetidinone derivatives for the treatment of atherosclerosis - Google Patents

Azetidinone derivatives for the treatment of atherosclerosis Download PDF

Info

Publication number
CA2225627A1
CA2225627A1 CA002225627A CA2225627A CA2225627A1 CA 2225627 A1 CA2225627 A1 CA 2225627A1 CA 002225627 A CA002225627 A CA 002225627A CA 2225627 A CA2225627 A CA 2225627A CA 2225627 A1 CA2225627 A1 CA 2225627A1
Authority
CA
Canada
Prior art keywords
oxoazetidin
diastereoisomer
benzylsulphinyl
acetamide
hexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002225627A
Other languages
English (en)
French (fr)
Inventor
Deirdre Mary Bernadette Hickey
Robert John Ife
Dashyant Dhanak
David Graham Tew
Colin Andrew Leach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513442.5A external-priority patent/GB9513442D0/en
Priority claimed from GBGB9515056.1A external-priority patent/GB9515056D0/en
Priority claimed from GBGB9515206.2A external-priority patent/GB9515206D0/en
Priority claimed from GBGB9516985.0A external-priority patent/GB9516985D0/en
Priority claimed from GBGB9525132.8A external-priority patent/GB9525132D0/en
Priority claimed from GBGB9608650.9A external-priority patent/GB9608650D0/en
Priority claimed from GBGB9608651.7A external-priority patent/GB9608651D0/en
Application filed by Individual filed Critical Individual
Publication of CA2225627A1 publication Critical patent/CA2225627A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C07D205/095Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002225627A 1995-07-01 1996-06-20 Azetidinone derivatives for the treatment of atherosclerosis Abandoned CA2225627A1 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
GBGB9513442.5A GB9513442D0 (en) 1995-07-01 1995-07-01 Novel compounds
GB9513442.5 1995-07-01
GBGB9515056.1A GB9515056D0 (en) 1995-07-22 1995-07-22 Novel compounds
GB9515056.1 1995-07-22
GBGB9515206.2A GB9515206D0 (en) 1995-07-25 1995-07-25 Novel compounds
GB9515206.2 1995-07-25
GBGB9516985.0A GB9516985D0 (en) 1995-08-18 1995-08-18 Novel compounds
GB9516985.0 1995-08-18
GB9525132.8 1995-12-08
GBGB9525132.8A GB9525132D0 (en) 1995-12-08 1995-12-08 Novel compounds
GBGB9608650.9A GB9608650D0 (en) 1996-04-26 1996-04-26 Novel compounds
GB9608650.9 1996-04-26
GBGB9608651.7A GB9608651D0 (en) 1996-04-26 1996-04-26 Novel compounds
GB9608651.7 1996-04-26

Publications (1)

Publication Number Publication Date
CA2225627A1 true CA2225627A1 (en) 1997-01-23

Family

ID=27562921

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002225627A Abandoned CA2225627A1 (en) 1995-07-01 1996-06-20 Azetidinone derivatives for the treatment of atherosclerosis

Country Status (23)

Country Link
EP (1) EP0840725A1 (de)
JP (1) JP2002515852A (de)
KR (1) KR19990028630A (de)
CN (1) CN1197452A (de)
AP (1) AP728A (de)
AU (1) AU708032B2 (de)
BG (1) BG102214A (de)
BR (1) BR9609445A (de)
CA (1) CA2225627A1 (de)
CZ (1) CZ422197A3 (de)
EA (1) EA199800109A1 (de)
HU (1) HUP9901153A3 (de)
IL (1) IL122650A0 (de)
MA (1) MA23922A1 (de)
MX (1) MX9800186A (de)
NO (1) NO976158L (de)
NZ (1) NZ311684A (de)
OA (1) OA10648A (de)
PE (1) PE8998A1 (de)
PL (1) PL324240A1 (de)
SK (1) SK178497A3 (de)
TR (1) TR199701762T1 (de)
WO (1) WO1997002242A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0869943A1 (de) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclische beta-lactame zur behandlung von atherosklerose
HUP9901359A3 (en) * 1996-04-26 2000-03-28 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
AU2001235466B2 (en) 2000-02-16 2004-04-22 Glaxo Group Limited Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
KR101730290B1 (ko) 2007-05-11 2017-04-25 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
CA2687079A1 (en) 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
EP2649053B1 (de) 2010-12-06 2015-11-04 Glaxo Group Limited Pyrimidinonverbindungen zur verwendung bei der behandlung von durch lp-pla2 bedingten krankheiten oder zuständen
US20130267544A1 (en) 2010-12-17 2013-10-10 Peter Adamson Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
EP2725024A4 (de) 2011-06-27 2014-12-03 Shanghai Inst Materia Medica Heterocyclische azolverbindung, herstellungsverfahren dafür, pharmazeutische zusammensetzung und verwendung davon
US9273054B2 (en) 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors
EP2739627A4 (de) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-dihydroimidazo-[1,2-c-] pyrimidin-5 (1h)-on-verbindungen als lp-pla²- inhibitoren
KR20150108896A (ko) 2013-01-25 2015-09-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Lp-pla2의 억제제로서의 비시클릭 피리미돈 화합물
RU2015135806A (ru) 2013-01-25 2017-03-03 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
UY35276A (es) 2013-01-25 2014-08-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos que inhiben la actividad de Lp-PLA2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
PE20230092A1 (es) 2019-11-09 2023-01-16 Shanghai Simr Biotechnology Co Ltd Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceuticas y uso del mismo
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
AP9701007A0 (en) * 1994-12-22 1997-07-31 Smithkline Beecham Plc Substituted azetidin-2-ones for treatment of atherosclerosis.

Also Published As

Publication number Publication date
HUP9901153A2 (hu) 1999-08-30
PE8998A1 (es) 1998-03-20
EP0840725A1 (de) 1998-05-13
WO1997002242A1 (en) 1997-01-23
JP2002515852A (ja) 2002-05-28
CN1197452A (zh) 1998-10-28
AP9701161A0 (en) 1998-01-31
NO976158L (no) 1998-02-25
KR19990028630A (ko) 1999-04-15
HUP9901153A3 (en) 1999-11-29
MX9800186A (es) 1998-07-31
NO976158D0 (no) 1997-12-30
EA199800109A1 (ru) 1998-10-29
TR199701762T1 (xx) 1998-05-21
PL324240A1 (en) 1998-05-11
AU6305096A (en) 1997-02-05
BR9609445A (pt) 1999-04-06
AP728A (en) 1999-01-29
AU708032B2 (en) 1999-07-29
NZ311684A (en) 2000-04-28
CZ422197A3 (cs) 1998-06-17
MA23922A1 (fr) 1996-12-31
BG102214A (en) 1998-08-31
OA10648A (en) 2002-09-25
SK178497A3 (en) 1998-07-08
IL122650A0 (en) 1998-08-16

Similar Documents

Publication Publication Date Title
CA2225627A1 (en) Azetidinone derivatives for the treatment of atherosclerosis
KR930008223B1 (ko) 소염제 및 퇴화 억제제로서 유용한 치환된 아제티디논
KR100235806B1 (ko) 저콜레스테롤혈증 치료제로서 유용한 황 치환된 아제티디논 화합물
NZ243669A (en) Heterocyclyl-substituted beta-lactam derivatives pharmaceutical compositions
JPH11500415A (ja) アテローム性動脈硬化症治療用置換アゼチジン−2−オン
US5229381A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
AU648345B2 (en) New substituted azetidinones as anti-inflammatory and antidegenerative agents
HU227492B1 (en) Intermediates for the preparation of agents having antifungal activity, processes for the preparation thereof
CN101657424A (zh) 双重作用的抗高血压药剂
JPH08507085A (ja) アゼチジノンの合成方法
JP2000509049A (ja) アテローム性動脈硬化症の治療用アゼチジノン誘導体
IE55839B1 (en) Azetidine compounds
JP2000509063A (ja) アテローム性動脈硬化症の治療用アゼチジノン誘導体
WO1997021675A1 (en) Monocyclic beta-lactame derivatives for treatment of atherosclerosis
JP3576193B2 (ja) ビフェニルメチル置換バレリルアミド誘導体
JPH11513704A (ja) 酸性ピラゾールの新誘導体、それらの製造方法、それらの薬剤としての用途、それらの新規な用途並びにそれらを含有する製薬組成物
JP2000501072A (ja) イミダゾール−n−ベンジルジオキソールの新誘導体、それらの製造方法、それらの薬剤としての用途、製薬組成物及び新規な用途
SK29295A3 (en) 4-oxo-azetidine-2-sulphonic acid amides and their salts, process for their production and their use
CA2058603C (en) Renin inhibiting polyhydroxymonoamides
JP2001172245A (ja) アミノブタン酸誘導体
EP0218415A1 (de) Verfahren zur Herstellung von Zwischenprodukten für 1-Carbapeneme und 1-Carbacepheme
JP2003212831A (ja) アミノブタン酸誘導体
KR20000065040A (ko) 아테롬성동맥경화증치료를위한아제티디논유도체
JPH054975A (ja) トリアゾール抗真菌剤

Legal Events

Date Code Title Description
FZDE Discontinued